
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Mogrify Ltd extends Series A financing to $46m
The additional commitment of US$10m that results in US$46m raised was made by the new lead investors Astellas Venture Management and Parkwalk...

Breakthrough in COPD treatment
Sanofi's duplimab (Dupixent®) showcased notable efficacy in reducing exacerbations and enhancing lung function in its second positive Phase III...

Breakthrough in microtia treatment
Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

AI helps classifying brain tumours during surgery
The findings presented in Nature by a team led by Jeroen De Ridder from UMC Utrecht demonstrate the potential feasibility of obtaining molecular...

Antiverse and GlobalBio Inc. extend collaboration
AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...